Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: A phase III, placebo-controlled, randomized study

Journal of Infectious Diseases

Volumn 203, Issue 12, 2011, Pages 1729-1738

  Langley, Joanne M ^a   Risi, George ^e   Caldwell, Michael ^f   Gilderman, Larry ^g   Berwald, Bruce ⁱ   Fogarty, Charles ^j   Poling, Terry ^k   Riff, Dennis ^l   Baron, Mira ^m   Frenette, Louise ^c   Sheldon, Eric ^h   Collins, Harry ⁿ   Shepard, Marc ^o   Dionne, Marc ^d   Brune, Daniel ^q   Ferguson, Linda ^b   Vaughn, David ^p   Li, Ping ^p   Fries, Louis ^p  

^a IWK HEALTH CENTRE   (Canada)

^b Colchester Research Group ^*  (Canada)

^c QandT Research Inc   (Canada)

^d Institut de recherche en santé publique de l'Universitré de Montréal   (Canada)

^e Infectious Disease Specialists   (United States)

^f Duchess County Department of Health   (United States)

^g University Clinical Research   (United States)

^h MIAMI RESEARCH ASSOCIATES   (United States)

ⁱ RADIANT RESEARCH   (United States)

^j Spartanburg Medical Research ^*  (United States)

^k Heartland Research Associates   (United States)

^l Advanced Clinical Research Institute   (United States)

^m Rapid Medical Research   (United States)

ⁿ Anderson and Collins Clinical Research Inc   (United States)

^o Accelovance Inc   (United States)

^p GLAXOSMITHKLINE   (United States)

^q Accelovance Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; CONTROLLED STUDY; CROHN DISEASE; CROSS REACTION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA NODOSUM; FACIAL NERVE PARALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEART INFARCTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RADICULITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEROCONVERSION; SINGLE BLIND PROCEDURE; TEMPORAL ARTERITIS; TROCHLEAR NERVE DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 79957453401     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir172     Document Type: Article

References (31)

1. World Health Organization. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. http://www.who.int/csr/disease/avian-influenza/ guidelines/200902-H5VaccineVirusUpdate.pdf. Published 2009. Accessed 15 September 2010.
2. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-46.
3. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53.
4. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9. (Pubitemid 47247854)
5. Rumke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88.
6. Moral S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity vaccine 2011; 29:2461-73.
7. US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines http://www.fda.gov/cber/gdlns/panfluvac.htm. 2007. Accessed 8 July 2010.
8. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/ 2006). London: European Agency for the Evaluation of Medicinal Products, 2007.
9. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71. (Pubitemid 38649075)
10. Kendal A, Pereira M, Skehel J. In: Kendal AP, Pereira MS, Skehel JJ, eds: Hemagglutination inhibition: concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: Centers for Disease Control and Prevention and Pan-American Health Organization, 1982: B17-35.
11. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43. (Pubitemid 29140593)
12. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-5. (Pubitemid 38649066)
13. Reed L, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-7.
14. Medical dictionary for regulatory activities. http://www.meddramsso.com/. Accessed 10 September 2010.
15. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442:448-52. (Pubitemid 44264793)
16. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-8.
17. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine 2007; 25:4983-4.
18. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008; 3:e1401.
19. Schwarz T, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90.
20. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9:1057-71.
21. Schwarz T, Horacek T, Knuf M. AS03-adjuvanted prepandemic H5N1 vaccine allows highly flexible prime-boost vaccination strategy. In: The 3rd European Influenza Conference; Villamoura, Portugal; 14-17 September 2008.
22. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90.
23. Banzhoff A, Gasparini R, Laghi-Pasini F, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384.
24. Gioia C, Castilletti C, Tempestilli M, et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for Influenza. Emerg Infect Dis 2008; 14:121-8.
25. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661-5. (Pubitemid 24359136)
26. Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 2007; 53:411-8. (Pubitemid 351664667)
27. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03(A)-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57.
28. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007; 79:320-5. (Pubitemid 46213197)
29. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91.
30. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77.
31. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115-22.